Relationship of Ethnic Origin, Gender, and Age to Blood Creatine Kinase Levels

American Journal of Medicine

Volumn 122, Issue 1, 2009, Pages 73-78

  Neal, Ryan C ^a   Ferdinand, Keith C ^b   Yčas, Joseph ^c   Miller, Elinor ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Association of Black Cardiologists   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Age; Creatine kinase; Gender; Race; Variation

Indexed keywords

CHOLESTEROL; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

ADULT; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ETHNICITY; FEMALE; GENDER; HISPANIC; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; RACE; SOUTH ASIA;

ADULT; AGED; AGING; CONTINENTAL POPULATION GROUPS; CREATINE KINASE; ETHNIC GROUPS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEX CHARACTERISTICS;

EID: 57949112975     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.08.033     Document Type: Article

References (22)

1. Black H.R., Quallich H., and Gareleck C.B. Racial differences in serum creatine kinase levels. Am J Med 81 (1986) 479-487
2. Clarkson P.M., Kearns A.K., Rouzier P., et al. Serum creatine kinase levels and renal function measures in exertional muscle damage. Med Sci Sports Exerc 38 (2006) 623-627
3. US Census Bureau, 2004. U.S. interim projections by age, sex, race, and Hispanic origin. http://www.census.gov/ipc/www/usinterimproj/ Accessed November 24, 2008
4. Meltzer H.Y., and Holy P.A. Black-white differences in serum creatine phosphokinase (CPK) activity. Clin Chim Acta 54 (1974) 215-224
5. Wong E.T., Cobb C., Umehara M.K., et al. Heterogeneity of serum creatine kinase activity among racial and gender groups of the population. Am J Clin Pathol 79 (1983) 582-586
6. Gledhill R.F., van Niekerk M.M., and van der Merwe C.A. Racial differences in serum creatine kinase levels. Am J Med 83 (1987) 365-366
7. Nevins M.A., Saran M., Bright M., and Lyon L.J. Pitfalls in interpreting serum creatine phosphokinase activity. JAMA 224 (1973) 1382-1387
8. Garcia W. Elevated creatine phosphokinase levels: association with large muscle mass. Another pitfall in evaluating clinical significance of total serum CPK activity. JAMA 228 (1974) 1395-1396
9. National Lipid Association Statin Safety Assessment Task Force, McKenney J.M., Davidson M.H., Jacobson T.A., and Guyton J.R. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97 suppl 8A (2006) 89C-94C
10. Ferdinand K.C., Clark L.T., Watson K.E., et al. ARIES Study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol 97 (2006) 229-235
11. Deedwania P.C., Gupta M., Stein M., et al., IRIS Study Group. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS trial). Am J Cardiol 99 (2007) 1538-1543
12. Lloret R., Yčas J., Stein M., Haffner S., and STARSHIP Study Group. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Am J Cardiol 98 (2006) 768-773
13. Insull Jr. W., Ghali J.K., Hassman D.R., et al., SOLAR Study Group. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc 82 (2007) 543-550
14. Newman C., Tsai J., Szarek M., et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 97 (2006) 61-67
15. Brewster L.M., Mairuhu G., Sturk A., and van Montfrans G.A. Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J 154 (2007) 655-661
16. Brewster L.M., Clark J.F., and van Montfrans G.A. Is greater tissue activity of creatine kinase the genetic factor increasing hypertension risk in black people of sub-Saharan African descent?. J Hypertens 18 (2000) 1537-1544
17. Brewster L.M., Mairuhu G., Bindraban N.R., et al. Creatine kinase activity is associated with blood pressure. Circulation 114 (2006) 2034-2039
18. Chan J., Hui R.L., and Levin E. Differential association between statin exposure and elevated levels of creatine kinase. Ann Pharmacother 39 (2005) 1611-1616
19. Apple F.S., Quist H.E., Doyle P.J., et al. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 49 (2003) 1331-1336
20. Gotto Jr. A.M. Statins, cardiovascular disease, and drug safety. Am J Cardiol 97 suppl 8A (2006) 3C-5C
21. Thompson P.D., Clarkson P.M., Rosenson R.S., and The National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol 97 (2006) 69C-76C
22. Sniderman A.D. Is there value in liver function test and creatine phosphokinase monitoring with statin use?. Am J Cardiol 94 suppl 9A (2004) 30F-34F